Early modifications of chemokine production and mRNA expression during rush venom immunotherapy

Cytokine

Volumn 10, Issue 9, 1998, Pages 706-712

  Akoum, Hikmat ^a   Duez, Catherine ^a   Fahy, Olivier ^a   Vorng, Han ^a   Wallaert, Benoît ^a   Tonnel, André Bernard ^a   Tsicopoulos, Anne ^a,b  

^a INSERM   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Chemokine; Mononuclear cells; Rush immunotherapy; Venom

Indexed keywords

BEE VENOM; CHEMOKINE; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ANAPHYLAXIS; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

APOIDEA;

EID: 0032169890     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0348     Document Type: Article

References (51)

1. 1. Hunt KJ, Valentine MD, Sobotka AK, Benton AW, Amodo FJ, Lichtenstein LM (1978) A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 299:157-161.
2. 2. Stadler B, Hirai K, Todokoro K, de Weck A (1985) Distinction of the human basophil promoting activity from human interleukin-3. Int Arch Allergy Appl Immunol 77:151-154.
3. 3. Sim T, Alam R, Forsythe P, Welter J, Lett-Brown M, Grant J (1992) Measurements of histamine releasing factor activity in individual nasal washings: relationship with atopy, basophil response, and membrane-bound IgE. J Allergy Clin Immunol 89:1157-1165.
4. 4. Alam R, Rozniecki J, Salmaj K (1984) A mononuclear cell-derived histamine-releasing factor (HRF) in asthmatic patients: histamine release from basophils in vitro. Ann Allergy 53:66-69.
5. 5. Kuna P, Alam R, Kuzminska B, Rozniecki J (1989) The effect of preseasonal immunotherapy on the production of histamine-releasing factor (HRF) by mononuclear cells from patients with seasonal asthma: Results of a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 83:816-824.
6. 6. Brunet C, Bedard PM, Lavoie A, Jobin M, Hebert J (1992) Allergic rhinitis to ragweed pollen. II. Modulation of histamine releasing factor production by specific immunotherapy. J Allergy Clin Immunol 89:87-94.
7. 7. Liao T, Hsieh K (1990) Altered production of histamine-releasing factor (HRF) activity and responsiveness to HRF after immunotherapy in children with asthma. J Allergy Clin Immunol 86:894-901.
8. 8. Mahmood T, Wall H, Sobus S, Stechshulte DJ, Abdou NI (1982) Modulation of venom-induced leukocyte histamine release by mononuclear cells. J Allergy Clin Immunol 70:445-451.
9. 9. Jutel M, Müller UR, Fricker M, Rihs S, Pichler WJ, Dahinden C (1996) Influence of bee venom immunotherapy on degranulation and leukotriene generation in human blood basophils. Clin Exp Allergy 26:1112-1118.
10. 10. Stephan V, Kühr J, Urbanek R (1989) Relevance of basophil histamine release changes during venom immunotherapy. Allergy 44:453-459.
11. 11. Baggiolini M, Dahinden CA (1994) CC chemokines in allergic inflammation. Immunol Today 15:127-133.
12. 12. Kaplan AP, Kuna P, Reddigari SR (1994) Chemokines as allergic mediators - relationship to histamine-releasing factors. Allergy 49:495-501.
13. 13. Lindley I, Aschauer H, Seifert JM, Lam C, Brunowsky W, Kownatzki E, Thelen M, Peveri P, Dewald B, Tscharner Vv, Walz A, Baggiolini M (1988) Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor. Proc Natl Acad Sci 85:9199-9205.
14. 14. Larsen CG, Anderson AO, Appella E, Oppenheim JJ, Matsushima K (1989) The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 243:1464-1468.
15. 15. Taub DD, Anver M, Oppenheim JJ, Longo DL, Murphy WJ (1996) T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest 97:1931-1941.
16. 16. Leonard EJ, Skeel A, Yoshimura T, Noer K, Kutvirt S, Van Epps D (1990) Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. J Immunol 144:1323-1330.
17. 17. Villar MTA, Douglass J, Shute J, Church MK, Holgate ST (1993) Interleukin-8 is a chemoattractant for eosinophils primed with interleukin-4. Am Rev Resp Dis 147:A242.
18. 18. Sehmi R, Cromwell O, Wardlaw AJ, Moqbel R, Kay AB (1993) Interleukin-8 is a chemoattractant for eosinophils purified from subjects with a blood eosinophilia but not from normal healthy subjects. Clin Exp Allergy 23:1027-1036.
19. 19. Kuna P, Reddigari SR, Kornfeld D, Kaplan AP (1991) IL-8 inhibits histamine release from human basophils induced by histamine-releasing factors, connective tissue activating peptide III, and IL-3. J Immunol 147:1920-1924.
20. 20. Bischoff SC, Baggiolini M, de-Week AL, Dahinden CA (1991) Interleukin 8-inhibitor and inducer of histamine and leukotriene release in human basophils. Biochem Biophys Res Commun 179:628-633.
21. 21. Dahinden CA, Kurimoto Y, De Week AL, Lindley I, Dewald B, Baggiolini M (1989) The neutrophil-activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3-primed basophils. J Exp Med 170:1787.
22. 22. Leonard ED, Skeel A, Yoshimura T (1991) Biological aspects of monocyte chemoattractant protein-1 (MCP-1). In Westwick J, Kunkel SL, Lundley I, eds. Chemotactic cytokines: biology of the inflammatory peptide supergene family. New York: Plenum 305:57-61.
23. 23. Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, Van Damme J (1995) Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 95:1370-1376.
24. 24. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K (1991) Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol 9:617-648.
25. 25. Alam R, Lett-Brown MA, Forsythe PA, Anderson-Walters DJ, Kenamore C, Kormos C, Grant JA (1992) Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils. J Clin Invest 89:723-728.
26. 26. Bischoff SC, Krieger M, Brunner T, Dahinden CA (1992) Monocyte chemotactic protein 1 is a potent activator of human basophils. J Exp Med 175:1271-1275.
27. 27. Kuna P, Reddigari SR, Rucinski D, Oppenheim JJ, Kaplan AP (1992) Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 175:489-493.
28. 28. Dahinden CA, Geiser T, Brunner T, Vontscharner V, Caput D, Ferrara P, Minty A, Baggiolini M (1994) Monocyte chemotactic protein 3 is a most effective basophil-and eosinophil-activating chemokine. J Exp Med 179:751-756.
29. 29. Schall TJ, Jongstra J, Dyer BJ, Jorgensen J, Claylberger C, Davis MM, Krensky AM (1988) A human T cell-specific molecule is a member of a new gene family. J Immunol 141:1018-1025.
30. 30. Bischoff SC, Krieger M, Brunner T, Rot A, von TV, Baggiolini M, Dahinden CA (1993) RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors. Eur J Immunol 23:761-767.
31. 31. Alam R, Stafford S, Forsythe P, Harrison R, Faubion D, Lett BM, Grant JA (1993) RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 150:3442-3448.
32. 32. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176:587-592.
33. 33. Ying S, Meng Q, Tabordabarata L, Corrigan CJ, Barkans J, Assoufi B, Moqbel R, Durham SR, Kay AB (1996) Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. Eur J Immunol 26:70-76.
34. 34. Schall TJ, Bacon K, Toy KJ, Goeddel DV (1990) Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 347:669-671.
35. 35. Kuna P, Reddigari SR, Schall TJ, Rucinski D, Viksman MY, Kaplan AP (1992) RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 149:636-642.
36. 36. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA (1992) Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. J Immunol 148:2390-2394.
37. 37. Kay A, Ying S, Varney V, Gaga M, Durham S, Moqbel R, Wardlaw A, Hamid Q (1991) Messenger RNA expression of the cytokine gene cluster, interleukin-3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. J Exp Med 173:775-778.
38. 38. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay B (1992) Predominant TH2-like bronchoalveolar T-Lymphocyte population in atopic asthma. N Engl J Med 326:298-304.
39. 39. Hsieh K, Chou C, Chiang B (1996) Immunotherapy suppresses the production of monocyte chemotactic and activating factor and augments the production of IL-8 in children with asthma. J Allergy Clin Immunol 98:580-587.
40. 40. Ohehir RE, Lake RA, Schall TJ, Yssel H, Panagiotopoulou E, Lamb JR (1996) Regulation of cytokine and chemokine transcription in a human TH2 type T-cell clone during the induction phase of anergy. Clin Exp Allergy 26:20-27.
41. 41. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, Hamid Q, Tonnel AB (1996) Venom immunotherapy modulates Interleukin-4 and Interferon-y messenger RNA expression of peripheral T lymphocytes. Immunology 87:593-598.
42. 42. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR (1995) Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 154:4187-4194.
43. 43. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW (1995) Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 25:828-838.
44. 44. Akdis CA, Akdis M, Blesken T, Wymann D, Alkan SS, Müller U, Blaser K (1996) Epitope-specific-T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 98:1676-1683.
45. 45. Hsieh K (1984) Change of lymphoproliferative responses of T-cell subsets to allergen and mitogen after hyposensitization in asthmatic children. J Allergy Clin Immunol 74:34-40.
46. 46. Hsieh K (1985) Altered interleukin 2 (IL-2) production and responsiveness after hyposensitization to house dust. J Allergy Clin Immunol 76:188-194.
47. 47. Hsieh K (1988) Decreased production of interleukin-2 receptor after immunotherapy to house dust. J Clin Immunol 8:171-178.
48. 48. Birnbaum J, Charpin D, Vervloet D (1993) Rapid hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 23:226-230.
49. 49. Legoux P, Minty C, Delpech B, Minty AJ, Shire D (1992) Simultaneous quantitation of cytokine mRNAs in interleukin-1b stimulated U373 human astrocytoma cells by a polymerisation chain reaction method involving co-amplification with an internal multispecific control. Eur Cytokine Netw 3:553-563.
50. 50. Lion T, Haas OA (1990) Nonradioactive labeling of probe with digoxigenin by polymerase chain reaction. Anal Biochem 188:335-337.
51. 51. Mukaida N, Shiroo M, Matsushima K (1989) Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol 143:1366-1371.